C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/62 (2006.01) A61K 38/46 (2006.01) C07K 14/515 (2006.01) C12N 9/22 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2073434
2073434 9112322 PCTABS00006 Regional mutagenesis of a gene for angiogenin to produce DNA sequences encoding mutant proteins having increased angiogenic activity are disclosed. Expression vectors containing these sequences are introduced into host cells and direct the production of mutant angiogenic proteins with markedly increased angiogenic activity. Replacement of amino acids in a region at or corresponding to residues 8-22 of angiogenin, with other amino acids, in particular, with amino acids corresponding to residues 7-21 of RNase, unexpectedly yields a mutant angiogenin/RNase hybrid protein with 10-fold increased angiogenic potency in the chorioallantoic membrane assay. Other in vivo and in vitro angiogenin-related activities are altered in the mutant hybrid protein. Mutant angiogenin/RNase hybrid proteins according to the present invention are useful therapeutic compositions to promote the development of a hemovascular network in a mammal or to promote wound healing, in particular, healing of torn or traumatized fibrocartilage material.
Bond Michael D.
Vallee Bert L.
President And Fellows Of Harvard College
Smart & Biggar
LandOfFree
Covalent angiogenin/rnase hybrids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Covalent angiogenin/rnase hybrids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Covalent angiogenin/rnase hybrids will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2071435